The data come from the Third National Health insurance and Nutrition Examination Study , a nationally representative sample of the population of the United States. Zeldin and his co-authors, however, point out that some extensive research demonstrates exposure to cats, particularly early in life, may be a protective element. Related StoriesNucala authorized for treatment of asthma patientsDifferent types of asthma respond differently to brand-new experimental treatmentFour types of gut bacteria can protect infants from asthmaThe NIH researchers looked at skin test data for ten allergens.Affinium announces AFN-1252 Phase I study results in staphylococcal infections Today the results of a fresh multiple ascending dose Phase I study of its novel Affinium Pharmaceuticals announced, selective-spectrum, anti-staphylococcal agent, AFN-1252 in a novel oral formulation. The study examined the tolerability, pharmacokinetics and basic safety of immediate launch tablets of AFN-1252. Cohorts of healthful volunteers were dosed 200mg, 300mg, and 400 mg of AFN-1252 once for 10 times daily. The pharmacokinetic results indicate that dosages of either 300 mg, and 400mg, once or 200 mg twice daily daily, met or exceeded exposures essential for the treatment of serious staphylococcal infections.